Agilent Technologies Inc. (NYSE: A) today introduced ClearSeq
AML, the first product in the ClearSeq line of next-generation
cancer research panels, which targets 48 selected exons in 20 of the
most commonly mutated genes found in acute myeloid leukemia.
Designed in collaboration with Dr.
Robert Ohgami and Dr.
Daniel Arber at the Stanford Department of Pathology, Stanford
University, ClearSeq AML provides comprehensive coverage of mutations
and enables swift progression of sample processing to analysis in less
than 48 hours. The AML gene panel will be followed by the release of
additional ClearSeq panels for cancer research throughout the coming
"We are pleased to introduce the ClearSeq family of products, a
comprehensive set of targeted NGS gene panels for cancer research," said
Jacob Thaysen, vice president and general manager of Agilent's
Diagnostics and Genomics Group. "ClearSeq NGS panels are
expert-identified products that will provide customers with a complete
end-to-end anatomical-to-molecular genomics portfolio that includes
solutions ranging from IHC for cancer diagnosis to NGS for cancer
Acute myeloid leukemia (AML) is the most common myeloid neoplasm
affecting adults, and the role of chromosomal structural variations in
its molecular pathogenesis is well documented. In recent years,
next-generation sequencing has led to a revolution in the study of
hematological malignancies and shown that insertions, deletions (indels)
and mutations play an essential part in the pathogenesis of AML. Genetic
information coupled with stadard anatomical findings has provided a
deeper characterization and classification of AML.
ClearSeq AML provides 99.9 percent design coverage of targeted coding
exons. Agilent's high-performance cancer panels enable the study of more
complex genomic alterations in cancer, and deliver quick and accurate
identification of relevant information. ClearSeq panels are based on
SureSelect and HaloPlex technology, offering superior sensitivity and
accuracy compared with other hybridization or PCR-based methods, thus
minimizing the risk of false-positive results. ClearSeq panels can be
easily incorporated into routine laboratory workflows. Sequence data
analysis and mutation reporting can be completed in three simple steps
To learn more about how to incorporate this powerful set of panels into
your research protocol, visit
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis,
life sciences, diagnostics, electronics and communications. The
company's 20,600 employees serve customers in more than 100 countries.
Agilent had revenues of $6.8 billion in fiscal 2013. Information about
Agilent is available at www.agilent.com.
In September 2013, Agilent announced plans to separate into two publicly
traded companies through a tax-free spinoff of its electronic
measurement business. On Aug. 1, 2014, the company's electronic
measurement business began operating as Keysight Technologies, Inc., a
wholly owned subsidiary. The separation is expected to be completed in
early November 2014.
This news release contains forward-looking statements as defined in the
Securities Exchange Act of 1934 and is subject to the safe harbors
created therein. The forward-looking statements contained herein
include, but are not limited to, information regarding the separation of
Agilent's electronic measurement business; future revenues, earnings and
profitability; the future demand for the company's products and
services; and customer expectations. These forward-looking statements
involve risks and uncertainties that could cause Agilent's results to
differ materially from management's current expectations. Such risks and
uncertainties include, but are not limited to, unforeseen changes in the
strength of our customers' businesses; unforeseen changes in the demand
for current and new products, technologies, and services; customer
purchasing decisions and timing, and the risk that we are not able to
realize the savings expected from integration and restructuring
In addition, other risks that Agilent faces include those detailed in
Agilent's filings with the Securities and Exchange Commission, including
our latest Form 10-K and Form 10-Q. Forward-looking statements are based
on the beliefs and assumptions of Agilent's management and on currently
available information. Agilent undertakes no responsibility to publicly
update or revise any forward-looking statement.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
[ Back To NFVZone's Homepage ]